University of Liverpool to use Touchlight’s rapid enzymatic dbDNA in fully personalised neoantigen cancer vaccine clinical study
Published: 4 April 2024
The UK’s Medical Research Council is funding a 10-patient Phase I study to deliver rapid personalised treatment for lung cancer patients.
Hampton, UK – 3 April 2024 – Touchlight, a CDMO enabling the development of genetic medicines with its enzymatic doggybone DNA (dbDNA™) technology, today announced an agreement with University of Liverpool for the use of dbDNA in the development of a fully-personalised therapeutic neoantigen DNA vaccine for patients with non-small cell lung cancer, to be given to patients at Clatterbridge Cancer Center, Liverpool.
Non-small cell lung cancer is the most common type of lung cancer, with almost 50,000 new diagnoses each year. It is the third most prevalent cancer in the UK and, globally, it is estimated that there were 2.2million new cases in 2020 alone.
The University of Liverpool researchers will be conducting a clinical trial that involves making a personalised cancer vaccine for each patient. The approach is designed to train the patient’s own immune system by targeting mutations in patients’ individual cancer and support patients who have not had sufficient benefit from standard immunotherapy.
Touchlight’s dbDNA technology produces a minimal, linear, double stranded, covalently closed DNA vector through an enzymatic manufacturing process.
dbDNA technology can deliver high purity GMP DNA in a small footprint at unprecedented speed and is ideally positioned to enable rapid individual personalised vaccines to cancer patients.
“We are delighted to work with Touchlight on developing this trial. The dbDNA approach offers a way to make vaccines very quickly, including for personalised treatments. We are very excited that we will be able to offer this clinical trial to patients with advanced lung cancer in Liverpool and expect that patients can be included starting in the 2nd half of 2024.”
Prof. Christian Ottensmeier, Chief investigator and shared lead of the project of the study
“this trials results from a long-standing collaboration between our team and Touchlight. The vaccine platform is completely novel and we believe has enormous promise in providing cancer vaccines that need to be made for each individual patient”.
Prof. Natalia Savelyeva, joint lead of the study
“We are delighted to be able to support the Liverpool team in the development of such an innovative therapeutic approach. Christian and his team are world-leaders in cancer immunology, and we are proud that our dbDNA technology is able to provide an improved turnaround time for a patient group with extremely high unmet need.”
Karen Fallen, CEO, Touchlight
About Touchlight
Touchlight is an innovation-driven leading CDMO pioneering enzymatic GMP DNA production to enable the genetic medicine revolution. As pioneers, with an FDA Drug Master File accepted in 2022 followed in 2025 with the world’s first cell-free DNA GMP license, Touchlight’s enzymatic DNA technology is on the cutting edge of AAV, mRNA, DNA vaccine, and gene editing technology with its state-of-the-art facility recognised by ISPE’s Facility of the Year Awards (FOYA) for Innovation.
With multiple client products already in the clinic, Touchlight’s evidence-based, synthetic DNA manufacturing solutions offer a scalable, sustainable alternative to plasmid DNA (pDNA) for all stages of pre-clinical, clinical and commercial development. The company and technology are built on the conviction that DNA is fundamental to the future of medicine. Traditional methods, based on bacterial fermentation, are slow, costly, and unable to meet the growing demands of genetic medicine due to limited scalability and speed. Founded in 2007, Touchlight’s team is inspired by breakthroughs in genetic medicine, recognising the urgent need for innovative DNA production techniques to support the future of genetic therapies.
For more information please contact:
Karen Fallen, Chief Executive Officer
Verna McErlane, Chief Commercial Officer
E: info@touchlight.com
T: +44 20 8481 9200
Get all the latest updates
No spam. Just interesting articles, and exclusive updates in your inbox every week.
